cancer C00-C97
Conditions
Interventions
Group 1: Within the framework of this research project, samples from patients with malignant diseases will be analyzed (mainly tissue and blood samples) via histological, genetic and immunological met
Sponsors
BioNTech SE
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: signed informed consent; Health condition, that allows planned interventions (according clinical standards); Hemoglobin value = 10,0 g / dl; Patient with suspected/confirmed malign tumor with either already excised/planned excision of tumor material and/or possibility of tumor biopsies exclusively taken for the research project
Exclusion criteria
Exclusion criteria: Known pregnancy or breastfeeding; Known acute or chronically active hepatitis infection, known HIV infection; Patients who are incapable to give consent or are not able to understand the nature of the project; serious concomitant disease or other circumstances (e.g. psychological, familial, sociological or geographical circumstances), which do not allow an adequate participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of this research project is to gain a profound understanding of genetic alterations within tumors as well as the tumor immunology of several entities (via histological, genetic and immunological analysis of tissue and blood samples) and to use this knowledge for further development of individualized cancer immunotherapies. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome is to establisch and optimize processes and methods. One aim is to be able to perform analytical procedures in the future (a) with small amounts of tumor material or (b) without tomur tissues. | — |
Countries
Germany
Contacts
Public ContactStephan Grabbe
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Outcome results
None listed